BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19530245)

  • 1. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?
    Corbin M; de Reyniès A; Rickman DS; Berrebi D; Boccon-Gibod L; Cohen-Gogo S; Fabre M; Jaubert F; Faussillon M; Yilmaz F; Sarnacki S; Landman-Parker J; Patte C; Schleiermacher G; Antignac C; Jeanpierre C
    Genes Chromosomes Cancer; 2009 Sep; 48(9):816-27. PubMed ID: 19530245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
    Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
    Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
    Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
    Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.
    Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S
    Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
    Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
    Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway.
    Kim MS; Yoon SK; Bollig F; Kitagaki J; Hur W; Whye NJ; Wu YP; Rivera MN; Park JY; Kim HS; Malik K; Bell DW; Englert C; Perantoni AO; Lee SB
    J Biol Chem; 2010 May; 285(19):14585-93. PubMed ID: 20220130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas.
    Ehrlich D; Bruder E; Thome MA; Gutt CN; von Knebel Doeberitz M; Niggli F; Perantoni AO; Koesters R
    Pediatr Dev Pathol; 2010; 13(1):1-8. PubMed ID: 19348510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
    Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
    Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wnt/beta-catenin pathway in Wilms tumors and prostate cancers.
    Tycko B; Li CM; Buttyan R
    Curr Mol Med; 2007 Aug; 7(5):479-89. PubMed ID: 17691963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms.
    Li Y; Wang J; Li X; Jia Y; Huai L; He K; Yu P; Wang M; Xing H; Rao Q; Tian Z; Tang K; Wang J; Mi Y
    Oncol Rep; 2014 Dec; 32(6):2680-6. PubMed ID: 25310451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
    Major MB; Camp ND; Berndt JD; Yi X; Goldenberg SJ; Hubbert C; Biechele TL; Gingras AC; Zheng N; Maccoss MJ; Angers S; Moon RT
    Science; 2007 May; 316(5827):1043-6. PubMed ID: 17510365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene.
    Akpa MM; Iglesias DM; Chu LL; Cybulsky M; Bravi C; Goodyer PR
    J Biol Chem; 2015 Jan; 290(4):2279-88. PubMed ID: 25331950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.